Press release
Psychosis in Parkinson's Disease and Alzheimer's Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market
(Albany, USA) DelveInsight's "Psychosis in Parkinson's Disease and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast-2034 report provides a comprehensive insight into the historical and projected epidemiology, along with market trends for Psychosis in Parkinson's Disease and Alzheimer's Disease in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To Know in detail about the Psychosis in Parkinson's Disease and Alzheimer's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psychosis in Parkinson's Disease and Alzheimer's Disease Market Forecast [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key facts of the Psychosis in Parkinson's Disease and Alzheimer's Disease Market Report:
* The Psychosis in Parkinson's Disease and Alzheimer's Disease market size was valued approximately USD 1,290 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* Acadia's NUPLAZID (pimavanserin) stands as the sole approved product for PDP (Parkinson's Disease Psychosis) in the US. While it is still under investigation for ADP (Alzheimer's Disease Psychosis), it carries a boxed warning concerning heightened mortality risks observed in elderly patients with psychosis related to dementia.
* Several medications are in various stages of development to address psychosis in Parkinson's Disease and Alzheimer's Disease, yet only a limited number are in advanced stages. Examples include Karuna Therapeutics' KarXT (xanomeline-trospium), Sunovion Pharmaceuticals' Ulotaront (SEP-363856), and Vanda Pharmaceuticals' FANAPT (iloperidone). These are expected to be introduced to the market within the forecast period spanning from 2023 to 2034.
* The total diagnosed prevalent cases of Parkinson's disease in the 7MM were estimated to be 2.6 million in 2023. The US accounted for approximately 45% of the total diagnosed prevalent cases of Parkinson's disease, while EU4 and the UK accounted for 45%, and Japan for 10% in 2023. These cases are expected to increase by 2034.
* Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of Parkinson's disease i.e. 487 thousand, follo
* In 2023, Germany contributed to roughly 18% of the total diagnosed prevalent cases of PD (Parkinson's Disease) within the 7MM. These cases are projected to rise at a Compound Annual Growth Rate (CAGR) of 1.7% during the study period from 2020 to 2034.
* Key Psychosis in Parkinson's Disease and Alzheimer's Disease Companies: ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
* Key Psychosis in Parkinson's Disease and Alzheimer's Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
* The Parkinson's Disease epidemiology based on gender analyzed that in the US, males diagnosed with PD are higher in number than females
* The Psychosis in Parkinson's Disease and Alzheimer's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psychosis in Parkinson's Disease and Alzheimer's Disease pipeline products will significantly revolutionize the Psychosis in Parkinson's Disease and Alzheimer's Disease market dynamics.
Psychosis in Parkinson's Disease and Alzheimer's Disease Overview
Psychosis in Parkinson's Disease (PD) and Alzheimer's Disease (AD) is a challenging neuropsychiatric symptom that significantly impacts patients and caregivers. It involves hallucinations, delusions, and altered perception, worsening disease burden and reducing quality of life.
In Parkinson's Disease, psychosis often manifests as visual hallucinations, typically mild at first but becoming more severe as the disease progresses. The primary cause is thought to be a combination of dopamine dysregulation from PD treatments and the underlying neurodegenerative process. Risk factors include older age, cognitive decline, and the use of dopaminergic medications. Management focuses on reducing or adjusting medications, and in severe cases, using antipsychotic drugs like pimavanserin that have fewer motor side effects.
In Alzheimer's Disease, psychosis usually presents as paranoid delusions and visual or auditory hallucinations, often occurring in the middle to late stages of the disease. It is linked to the progressive degeneration of brain regions involved in perception and cognition. Treatment may involve antipsychotics, although their use is limited due to potential side effects and the risk of worsening cognitive symptoms.
Early recognition and a multidisciplinary approach are crucial in managing psychosis in PD and AD, balancing symptom control with minimizing medication side effects and addressing the needs of patients and caregivers.
Get a Free sample for the Psychosis in Parkinson's Disease and Alzheimer's Disease Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market [https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology Segmentation:
The Psychosis in Parkinson's Disease and Alzheimer's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
* Total Prevalence of Psychosis in Parkinson's Disease and Alzheimer's Disease
* Prevalent Cases of Psychosis in Parkinson's Disease and Alzheimer's Disease by severity
* Gender-specific Prevalence of Psychosis in Parkinson's Disease and Alzheimer's Disease
* Diagnosed Cases of Episodic and Chronic Psychosis in Parkinson's Disease and Alzheimer's Disease
Download the report to understand which factors are driving Psychosis in Parkinson's Disease and Alzheimer's Disease epidemiology trends @ Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Psychosis in Parkinson's Disease and Alzheimer's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psychosis in Parkinson's Disease and Alzheimer's Disease market or expected to get launched during the study period. The analysis covers Psychosis in Parkinson's Disease and Alzheimer's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Psychosis in Parkinson's Disease and Alzheimer's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Psychosis in Parkinson's Disease and Alzheimer's Disease Therapies and Key Companies
* KarXT: Karuna Therapeutics
* Ulotaront: Sunovion Pharmaceuticals
* FANAPT: Vanda PharmaceuticalsF
* ITI-1284: Intra-Cellular Therapeutics
* MK-8189: Merck Sharp & Dohme
Discover more about therapies set to grab major Psychosis in Parkinson's Disease and Alzheimer's Disease market share @ Psychosis in Parkinson's Disease and Alzheimer's Disease Treatment Landscape [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Psychosis in Parkinson's Disease and Alzheimer's Disease Market Strengths
* Increased awareness and a more in-depth understanding of the disease pathophysiology has improved diagnosis and treatment.
* The recent US FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with PD Psychosis, indicates a positive change in treatment paradigm.
Psychosis in Parkinson's Disease and Alzheimer's Disease Market Opportunities
* There are opportunities for pharma players to develop therapies with improved safety and tolerability profiles, effectively reducing symptoms and preventing the recurrence of Psychosis in PD and AD.
* Advancement in biomarkers for cognitive decline allows precise diagnosis and individualized treatments
Scope of the Psychosis in Parkinson's Disease and Alzheimer's Disease Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Psychosis in Parkinson's Disease and Alzheimer's Disease Companies: ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
* Key Psychosis in Parkinson's Disease and Alzheimer's Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
* Psychosis in Parkinson's Disease and Alzheimer's Disease Therapeutic Assessment: Psychosis in Parkinson's Disease and Alzheimer's Disease current marketed and Psychosis in Parkinson's Disease and Alzheimer's Disease emerging therapies
* Psychosis in Parkinson's Disease and Alzheimer's Disease Market Dynamics: Psychosis in Parkinson's Disease and Alzheimer's Disease market drivers and Psychosis in Parkinson's Disease and Alzheimer's Disease market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Psychosis in Parkinson's Disease and Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's Disease and Alzheimer's Disease Market Access and Reimbursement
To know more about Psychosis in Parkinson's Disease and Alzheimer's Disease companies working in the treatment market, visit @ Psychosis in Parkinson's Disease and Alzheimer's Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Report Introduction
2. Executive Summary for Psychosis in Parkinson's Disease and Alzheimer's Disease
3. SWOT analysis of Psychosis in Parkinson's Disease and Alzheimer's Disease
4. Psychosis in Parkinson's Disease and Alzheimer's Disease Patient Share (%) Overview at a Glance
5. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Overview at a Glance
6. Psychosis in Parkinson's Disease and Alzheimer's Disease Disease Background and Overview
7. Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Psychosis in Parkinson's Disease and Alzheimer's Disease
9. Psychosis in Parkinson's Disease and Alzheimer's Disease Current Treatment and Medical Practices
10. Psychosis in Parkinson's Disease and Alzheimer's Disease Unmet Needs
11. Psychosis in Parkinson's Disease and Alzheimer's Disease Emerging Therapies
12. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Outlook
13. Country-Wise Psychosis in Parkinson's Disease and Alzheimer's Disease Market Analysis (2020-2034)
14. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Access and Reimbursement of Therapies
15. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Drivers
16. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Barriers
17. Psychosis in Parkinson's Disease and Alzheimer's Disease Appendix
18. Psychosis in Parkinson's Disease and Alzheimer's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psychosis-in-parkinsons-disease-and-alzheimers-disease-treatment-market-2034-clinical-trials-ema-pdma-fda-approvals-epidemiology-therapies-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/market-assessment-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psychosis in Parkinson's Disease and Alzheimer's Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight here
News-ID: 3736408 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
